Trials / Completed
CompletedNCT06129812
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer According to Tumor-vessel Relationship and CA 19-9 Levels
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,132 (actual)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
Detailed description
The 1,132 patients with resectable or borderline resectable PDAC who underwent surgery between 2007 and 2021 were retrospectively reviewed. Patients with resectable PDAC without contact of major vessels (R-no contact) (n=651), with contact of portal vein or superior mesenteric vein (PV/SMV) ≤180° (R-contact) (n=306), and borderline resectable PDAC without arterial involvement (BR-V) (n=175) were analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neoadjuvant treatment | Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC. |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
- First posted
- 2023-11-13
- Last updated
- 2023-11-13
Source: ClinicalTrials.gov record NCT06129812. Inclusion in this directory is not an endorsement.